Close Relationship Between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jun 28

PMID 37373109

Authors

Adhara Lazaro

Patrick Stoll

Dominik von Elverfeldt

Wolfgang Kreisel

Peter Deibert

Affiliations

Soon will be listed here.

Abstract

It is unclear to what extent systemic arterial blood pressure influences portal pressure. This relationship is clinically important as drugs, which are conventionally used for therapy of portal hypertension, may also influence systemic arterial blood pressure. This study investigated the potential correlation between mean arterial (MAP) and portal venous pressure (PVP) in rats with healthy livers. In a rat model with healthy livers, we investigated the effect of manipulation of MAP on PVP. Interventions consisted of 0.9% NaCl (group 1), 0.1 mg/kg body weight (bw) Sildenafil (low dose), an inhibitor of phosphodiesterase-5 (group 2), and 1.0 mg/kg bw Sildenafil (high dose, group 3) in 600 µL saline injected intravenously. Norepinephrine was used to increase MAP in animals with circulatory failure while PVP was monitored. Injection of the fluids induced a transient drop in MAP and PVP, probably due to a reversible cardiac decompensation. The drop in MAP and drop in PVP are significantly correlated. The time lag between change in MAP and change in PVP by 24 s in all groups suggests a cause-and-effect relationship. Ten minutes after the injection of the fluid, cardiac function was normalized. Thereafter, MAP gradually decreased. In the NaCl group, PVP decreases by 0.485% for a 1% drop of MAP, by 0.550% in the low-dose sildenafil group, and by 0.651% in the high-dose sildenafil group ( < 0.05 for difference group two vs. group one, group three vs. group one, and group three vs. group two). These data suggest that Sildenafil has an inherent effect on portal pressure that exceeds the effect of MAP. Injection of norepinephrine led to a sudden increase in MAP followed by an increase in PVP after a time lag. These data show a close relationship between portal venous pressure and systemic arterial pressure in this animal model with healthy livers. A change in MAP is consequently followed by a change in PVP after a distinct time lag. This study, furthermore, suggests that Sildenafil influences portal pressure. Further studies should be performed in a model with cirrhotic livers, as these may be important in the evaluation of vasoactive drugs (e.g., PDE-5-inhibitors) for therapy of portal hypertension.

References

DAmico G, Malizia G, Bosch J . Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension?. Hepatology. 2016; 63(6):1771-3. DOI: 10.1002/hep.28502. View

Krag A, Wiest R, Albillos A, Gluud L . The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012; 61(7):967-9. DOI: 10.1136/gutjnl-2011-301348. View

Ideo G, Bellati G, Fesce E, Grimoldi D . Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology. 1988; 8(1):6-9. DOI: 10.1002/hep.1840080103. View

Bosch J, Iwakiri Y . The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatol Int. 2017; 12(Suppl 1):1-10. DOI: 10.1007/s12072-017-9827-9. View

Ramirez G, Briceno J, Rojas A . Statins and portal hypertension: a new pharmacological challenge. Curr Vasc Pharmacol. 2012; 10(6):767-72. DOI: 10.2174/157016112803520918. View

Iwakiri Y, Shah V, Rockey D . Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol. 2014; 61(4):912-24. PMC: 4346093. DOI: 10.1016/j.jhep.2014.05.047. View

Boyer J, Chatterjee C, Iber F, Basu A . Effect of plasma-volume expansion on portal hypertension. N Engl J Med. 1966; 275(14):750-5. DOI: 10.1056/NEJM196610062751403. View

Tripathi D, Hayes P . Beta-blockers in portal hypertension: new developments and controversies. Liver Int. 2013; 34(5):655-67. DOI: 10.1111/liv.12360. View

Colle I, De Vriese A, Van Vlierberghe H, Lameire N, Devos M . Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int. 2004; 24(1):63-8. DOI: 10.1111/j.1478-3231.2004.00892.x. View

10.

Abraldes J, Garcia-Tsao G . The Design of Clinical Trials in Portal Hypertension. Semin Liver Dis. 2017; 37(1):73-84. DOI: 10.1055/s-0036-1597891. View

11.

Thabut D, Shah V . Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?. J Hepatol. 2010; 53(5):976-80. DOI: 10.1016/j.jhep.2010.07.004. View

12.

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

13.

Albillos A, Lledo J, Rossi I, Perez-Paramo M, Tabuenca M, Banares R . Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology. 1995; 109(4):1257-65. DOI: 10.1016/0016-5085(95)90586-3. View

14.

Brusilovskaya K, Konigshofer P, Schwabl P, Reiberger T . Vascular Targets for the Treatment of Portal Hypertension. Semin Liver Dis. 2019; 39(4):483-501. DOI: 10.1055/s-0039-1693115. View

15.

de Franchis R, DellEra A, Primignani M . Diagnosis and monitoring of portal hypertension. Dig Liver Dis. 2008; 40(5):312-7. DOI: 10.1016/j.dld.2007.12.007. View

16.

Bolognesi M, Di Pascoli M, Verardo A, Gatta A . Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014; 20(10):2555-63. PMC: 3949264. DOI: 10.3748/wjg.v20.i10.2555. View

17.

Iwakiri Y, Trebicka J . Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep. 2021; 3(4):100316. PMC: 8318926. DOI: 10.1016/j.jhepr.2021.100316. View

18.

Fernandez M . Molecular pathophysiology of portal hypertension. Hepatology. 2014; 61(4):1406-15. DOI: 10.1002/hep.27343. View

19.

Deibert P, Schumacher Y, Ruecker G, Opitz O, Blum H, Rossle M . Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. Aliment Pharmacol Ther. 2006; 23(1):121-8. DOI: 10.1111/j.1365-2036.2006.02735.x. View

20.

Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P . Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci. 2021; 22(19). PMC: 8508925. DOI: 10.3390/ijms221910372. View